Think you probably already know. Terry is Frank and Rose. This terry id guy get off on multi ids to back up and build up his terry ids. This guys needs help. He got slammed on AMLN at above and seemed to have loss it ever since then.
heads up-one of your posters terry visited our board with comments about the gigigle guy and started his on gigigle id on our board. He could be gigigle on both boards. al
getting smacked pretty hard.depending on how long this correction goes on - $27.20 possible Giggle Giggle
From Luke Timmerman last week:
Genomic Health. The Redwood City, CA-based company (NASDAQ: GHDX) is widely admired in diagnostics because it proved to skeptical insurers that diagnostics aren’t just cheap commodities anymore—they provide information about health that’s quite valuable. Genomic Health has continued to thrive and grow under two CEOs—Randy Scott and Kim Popovits. It is now rolling out new iterations of its original OncotypeDx product that predict the risk of recurrence for patients with prostate and colon cancer, proving it’s not a one-hit wonder in breast cancer. By showing the way in molecular diagnostics, Genomic Health has inspired other entrepreneurs to think big about how new instruments can be used to better predict and prevent disease before doctors have to turn to high-priced and often-toxic therapies. The company could be highly profitable tomorrow if it wanted to be, but instead it chooses to get by on low margins while continuing to invest in the future. It’s a sure sign of a company with a view toward long-term excellence.
All readers may want to read the June 27, 2013 "letter to investors" on Genomic Healths site for answers about how they do their science.
that is the truth with this stock. As soon as we noticed terry was hyping this stock we knew SHORTING was a given. It is just amazing how that works most every time. Giggle Giggle
WOW, what a drop....down how much now. NO WAY this does not go lower...Like trying to catch a dropping knife...insider selling is never a good sign. Giggle Giggle
frankyassissi: we're both bulls on ghdx but here's the reality. I was optimistic that guidance for FY'14 would come in much better; so did the street. In the cc from last Jan '13 the co. guided that OncoDx for prostate should begin to get traction by Q4 2013. I think the sell off is justified. Probably a good opportunity to begin to build a position, and add more if things get ugly. The s.p. might be stagnant for some months, no? Doesn't appear to be any near-term catalyst here. Ideas?
Put it on a 2 Year chart and how can anybody say this is NOT rigged by the boys.
Market Fraud, Market Manipulation, Truly a shame. Came up on the 52 Week low list.
I remember when some good people talked about how this viable company is valuable.
Only to the Market Manipulating Banksters.
Zacks is nothing short of a paid stoolie. I assure you Zacks UBS and the other that downgraded are helping those who are long Genomic Health.Selling at 3x to revenues with no debt Gemonic health, Felix Julian and myself only add when they push it down. Steve Burrill thinks this company is one of the best -investments - in biotech.We dont care what the price is today - we care what it is when we sell Good Luck
I agree....On the last recent dip in early Jan I bought shares and then traded out of them when the current market rout began, but re-entered my position this morning. I usually don't trade all that much, but have learned that bio-tech often gets hammered more than the mkt. averages when ill winds blow. Just got lucky, really. I'll add more if the sp gets worse. Long term, this will get to $50+ without much trouble.
Got out 20% ago. The call was 11% growth but guidance was on the lower side,but 20%? When promising bios are about to announce a merger a takeover they push the stock down as hard as possible.Bet you will soon see the Bakers newest SEC doc.accumulating.buying a lot.just hit below 36 wow!
So true.The pieces of the company in R&D in laying out the international markets and science verification and a stock selling for 3 X revenues means the groundwork is being laid for a Baker Brothers sale.
Genomic Health Announces Results of Oncotype DX(R) Colon Cancer Studies Presented at 2014 American Society of Clinical Oncology Gastrointestinal Cancer (ASCO GI) Symposium
New data show real-life impact of Oncotype DX on treatment decisions, underscore clinical validity and utility of the test GHDX) today announced results from the Oncotype DX® colon cancer test studies that were recently presented at the 2014 American Society of Clinical Oncology Gastrointestinal Cancer Symposium (ASCO GI). Presentations highlighted the robust body of clinical evidence for the Oncotype DX colon cancer test and its real-life impact on patient and physician treatment decisions, underscoring the practice-changing value of this test.
Prospective study demonstrated real-life impact on physician and patient treatment decisions
Through an analysis of physician recommendations and patient treatment preferences before and after receiving the Oncotype DX colon cancer test results, this study demonstrated that the test greatly increased concordance between physician and patient treatment choice (from 66 percent to 96 percent). Furthermore, the evaluation showed that the quantitative information provided by the Recurrence Score® result influenced a majority of patients' treatment decisions (85 percent) and physicians' treatment recommendations (69 percent), and it increased physicians' confidence in their own recommendations (84 percent). Patients' anxiety was also significantly reduced, which may improve adherence to their treatment plan and ultimately lead to better health outcomes.
"The additional information provided by the Oncotype DX test enables me and my patients to make better informed decisions about their individual treatment," said Steven Alberts, M.D., chair of the Division of Medical Oncology at Mayo Clinic Cancer Center, Roche
CHOOO CHOOO, let's keep this moving up....next stop $34.65 then sell....wash, rinse and repeat. Giggle, Giggle